‘Red light’ cancer meds face price cuts, delisting
By Megan Brodie 2 months ago | In Politics, Products, Reimbursement- 2 months ago
5 August 2026 A trial of a post-marketing monitoring scheme has flagged three leading medicines…
This is subscriber-only content. Please login to continue reading.